Drug class
Antiparkinsonian Amantadine Formulations
"Antiparkinsonian Amantadine Formulations" is not a formal FDA Established Pharmacologic Class, but rather a clinical and formulary categorization designating oral delivery systems of amantadine—including immediate-release and extended-release capsules and tablets—indicated for neurologic movement disorders. Read more about Antiparkinsonian Amantadine Formulations
27 drugs in this class 25 manufacturers
Drugs in Antiparkinsonian Amantadine Formulations
AMANTADINE (amantadine HCl)
AMANTADINE (amantadine HCl)
AMANTADINE (amantadine HCl)
AMANTADINE (amantadine HCl)
AMANTADINE (amantadine HCl)
AMANTADINE (amantadine HCl)
AMANTADINE (amantadine HCl)
AMANTADINE (amantadine HCl)
"Antiparkinsonian Amantadine Formulations" is not a formal FDA Established Pharmacologic Class, but rather a clinical and formulary categorization designating oral delivery systems of amantadine—including immediate-release and extended-release capsules and tablets—indicated for neurologic movement disorders.
Therapeutic activity is primarily mediated through weak, uncompetitive N-methyl-D-aspartate receptor antagonism and modulation of central dopaminergic transmission.
Formulations in this category are utilized in the management of idiopathic Parkinson disease, post-encephalitic or drug-induced extrapyramidal symptoms, and levodopa-induced dyskinesia or motor fluctuations.
-
connectrx.com
"Antiparkinsonian Amantadine Formulations" is not a formal FDA Established Pharmacologic Class, but rather a clinical and formulary categorization designating oral delivery systems of amantadine—including immediate-release and extended-release capsules and tablets—indicated for neurologic movement disorders
-
fda.gov
"Antiparkinsonian Amantadine Formulations" is not a formal FDA Established Pharmacologic Class, but rather a clinical and formulary categorization designating oral delivery systems of amantadine—including immediate-release and extended-release capsules and tablets—indicated for neurologic movement disorders
-
fda.gov
"Antiparkinsonian Amantadine Formulations" is not a formal FDA Established Pharmacologic Class, but rather a clinical and formulary categorization designating oral delivery systems of amantadine—including immediate-release and extended-release capsules and tablets—indicated for neurologic movement disorders
-
fda.gov
Therapeutic activity is primarily mediated through weak, uncompetitive N-methyl-D-aspartate receptor antagonism and modulation of central dopaminergic transmission
-
drugs.com
Therapeutic activity is primarily mediated through weak, uncompetitive N-methyl-D-aspartate receptor antagonism and modulation of central dopaminergic transmission Formulations in this category are utilized in the management of idiopathic Parkinson disease, post-encephalitic or drug-induced extrapyramidal symptoms, and levodopa-induced dyskinesia or motor fluctuations
-
parkinson.org
Formulations in this category are utilized in the management of idiopathic Parkinson disease, post-encephalitic or drug-induced extrapyramidal symptoms, and levodopa-induced dyskinesia or motor fluctuations
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.